CPK4

CPK4 is an experimental **small-molecule potassium channel blocker** identified in a structure-based screening campaign aimed at finding new inhibitors of **KCNT1**, a sodium-activated potassium channel whose gain-of-function variants cause severe developmental and epileptic encephalopathies. In the cited preclinical study, CPK4 was one of five hit compounds that showed strong KCNT1-blocking activity in a fluorescence assay, and patch-clamp testing supported higher KCNT1-blocking potency than quinidine with reported selectivity over hERG and Kv7.2 channels. Publicly available information from the provided source does not define a full chemical name, developer company, formulation, route, or clinical development program for CPK4, so it should currently be regarded as an early research-stage lead compound for potential treatment of **KCNT1-related epilepsy** rather than a clinically established drug.